Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.57 +1.3%	$1.53	$1.05 ▼ $5.17	$167.84M	0.3	1.39 million shs	608,330 shs
GANX Gain Therapeutics	$1.49 -3.6%	$1.72	$0.89 ▼ $3.19	$46.46M	0.1	290,429 shs	285,468 shs
LYEL Lyell Immunopharma	$11.32 +2.2%	$10.21	$7.65 ▼ $32.40	$171.26M	-0.19	68,428 shs	49,831 shs
SLS SELLAS Life Sciences Group	$1.60 +0.6%	$1.78	$0.77 ▼ $2.27	$158.65M	2.26	2.41 million shs	1.52 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.29%	+2.61%	+8.28%	+24.60%	+31.93%
GANX Gain Therapeutics	-3.56%	+2.05%	-11.31%	-23.20%	+56.43%
LYEL Lyell Immunopharma	+2.17%	-4.15%	+21.20%	+41.50%	-59.86%
SLS SELLAS Life Sciences Group	+0.63%	+0.63%	-23.44%	+2.56%	+36.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.009 of 5 stars	3.6	1.0	1.9	1.7	0.6
GANX Gain Therapeutics	3.1232 of 5 stars	3.6	5.0	3.4	0.0	0.6
LYEL Lyell Immunopharma	3.3213 of 5 stars	2.8	5.0	0.0	3.3	1.3
SLS SELLAS Life Sciences Group	2.233 of 5 stars	3.5	1.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	455.05% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	450.34% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	32.51% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	337.50% Upside

Current Analyst Ratings Breakdown

Latest GANX, LYEL, ACRS, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.08	N/A	N/A	$1.44 per share	1.09
GANX Gain Therapeutics	$50K	896.09	N/A	N/A	$0.28 per share	5.32
LYEL Lyell Immunopharma	$65K	2,691.90	N/A	N/A	$26.21 per share	0.43
SLS SELLAS Life Sciences Group	$1M	159.65	N/A	N/A	$0.13 per share	12.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	N/A
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/14/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest GANX, LYEL, ACRS, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	-$0.13	+$0.01	-$0.13	$1.34 million	$1.78 million
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
GANX Gain Therapeutics	0.05	2.22	2.22
LYEL Lyell Immunopharma	N/A	7.49	7.49
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
GANX Gain Therapeutics	11.97%
LYEL Lyell Immunopharma	66.05%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
GANX Gain Therapeutics	7.18%
LYEL Lyell Immunopharma	22.30%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
GANX Gain Therapeutics	20	30.07 million	27.91 million	Optionable
LYEL Lyell Immunopharma	270	15.46 million	12.01 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.38 million	Not Optionable

GANX, LYEL, ACRS, and SLS Headlines

Recent News About These Companies

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7 at 8:30 AM | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6 at 10:28 AM | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

July 30, 2025 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00

July 16, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What Happened

July 9, 2025 | marketbeat.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, LYEL, ACRS, and SLS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.57 +0.02 (+1.29%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$1.54 -0.03 (-1.59%)

As of 08/7/2025 07:46 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Gain Therapeutics NASDAQ:GANX

$1.49 -0.06 (-3.56%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$1.54 +0.05 (+3.62%)

As of 08/7/2025 05:59 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Lyell Immunopharma NASDAQ:LYEL

$11.32 +0.24 (+2.17%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$11.34 +0.03 (+0.22%)

As of 08/7/2025 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.60 +0.01 (+0.63%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$1.62 +0.02 (+1.25%)

As of 08/7/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time